Interstitial Lung Disease News

Patients with interstitial lung disease and surfactant-related gene mutations showed progressive lung function decline and reduced survival that was comparable to that of other ILD groups, according to results published in CHEST.

Patients with asthma, COPD and interstitial lung disease have reduced SARS-CoV-2 vaccine-specific antibody, B-cell and T-cell responses, which signals poorer protection against COVID-19, according to results published in ERJ Open Research.

The FDA granted breakthrough therapy designation to an oral lysophosphatidic acid receptor 1 antagonist that lowered the rate of percent-predicted FVC decline among patients with progressive pulmonary fibrosis.

HONOLULU — Treatment with nintedanib plus pirfenidone resulted in a similar frequency of adverse events as monotherapy among patients with idiopathic pulmonary fibrosis, according to a systemic review presented at the CHEST Annual Meeting.

HONOLULU — Risk for mortality and hospitalization did not differ between patients with idiopathic pulmonary fibrosis taking 100 mg or 150 mg nintedanib twice daily, according to a real-world analysis presented at the CHEST Annual Meeting.

Patients with sarcoidosis receiving 40 mg per day of prednisolone had comparable rates of treatment failure and adverse effects to patients receiving 20 mg per day, according to a European Respiratory Society International Congress presentation.

Patients with systemic sclerosis-associated interstitial lung disease who receive nintedanib demonstrate a higher risk for malnutrition, compared with placebo, according to data published in Arthritis Care & Research.

Receiving an oral lysophosphatidic acid receptor 1 antagonist for 26 weeks lowered the rate of percent predicted FVC decline in progressive pulmonary fibrosis, according to a European Respiratory Society International Congress presentation.

SAN DIEGO — Rheumatologists should stratify patients with systemic sclerosis-associated interstitial lung disease into phenotypes in order to closely monitor those with progressing disease, according to a speaker here.

Given the rarity of pulmonary fibrosis, pulmonologists are constantly seeking to know more about the disease and advance research on treatment options.